Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Overview of Theravance Biopharma Inc
Theravance Biopharma Inc (NASDAQ: TBPH) is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. With a solid foundation built on internally discovered product candidates and strategic partnerships, the company has positioned itself as a key player in addressing critical unmet needs in the treatment of respiratory and neurological disorders. Utilizing advanced research methodologies and precision medicine approaches, Theravance Biopharma aims to maximize therapeutic efficacy while minimizing systemic side effects.
Core Business and Product Portfolio
At its core, Theravance Biopharma invests heavily in the development of small-molecule drugs designed for organ-selective targeting. This strategy is exemplified by its FDA-approved product, YUPELRI (revefenacin) inhalation solution, which is the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company’s approach in leveraging organ-selectivity not only underpins its ability to deliver sustained improvements in pulmonary function but also highlights its commitment to addressing patient-specific needs through enhanced treatment outcomes.
Innovative Research and Development Strategy
Theravance Biopharma distinguishes itself through a robust, internally focused research and development platform. The company pioneers a new generation of small molecule drugs by applying its expertise in organ-selectivity to target diseases biologically. This approach is particularly significant in the field of inflammation and immunology where therapeutic indices can be expanded, thereby maximizing benefits while reducing systemic exposure. In addition to YUPELRI, the company is advancing a pipeline of promising product candidates, including ampreloxetine—an investigational agent developed as a once-daily norepinephrine reuptake inhibitor intended to manage symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA).
Strategic Collaborations and Market Position
Theravance Biopharma’s operational strategy is enhanced by strategic collaborations with other pharmaceutical companies. These partnerships not only complement the company’s internal discovery efforts but also provide additional avenues to accelerate clinical development, expand market reach, and optimize commercialization strategies. The unique collaboration dynamics, such as those with global commercial partners, reinforce the company’s capacity to navigate the competitive landscape and address market challenges effectively, making it a significant entity within the biopharmaceutical sector.
Expertise and Industry Credibility
The company’s demonstrated ability to innovate in the field of organ-selective medicine reflects deep scientific expertise and rigorous research methodologies. By combining academic research, clinical insights, and regulatory know-how, Theravance Biopharma has established a reputation for both innovation and reliability in its therapeutic niche. The consistent focus on delivering measurable clinical benefits, backed by peer-reviewed studies and rigorous clinical trial designs, further enhances its authority within the competitive landscape of respiratory and neurological therapeutics.
Comprehensive Business Model and Value Proposition
Theravance Biopharma’s business model revolves around the development and commercialization of a targeted portfolio that maximizes therapeutic efficacy while addressing market needs through innovative medicine. The company’s dual focus on an approved, commercially successful product and a robust pipeline of candidate drugs positions it well within its market segment. Although complex market dynamics and regulatory challenges exist, its disciplined approach to research and clinical development reinforces its stand as a scientifically driven enterprise dedicated to creating medicines that make a difference.
Investor and Market Insights
For investors and market researchers, Theravance Biopharma represents a blend of innovative research coupled with a commercially validated product. Its trajectory showcases an interplay between internally driven discovery and collaborative strength, which is reflected in its ever-expanding clinical developments and its focused approach toward addressing diseases with significant unmet patient needs. The company continually refines its research and development strategies, ensuring that its product portfolio remains both relevant and robust in an evolving therapeutic landscape.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).
The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.
A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) has announced new analyses of their Phase 3 ampreloxetine program for Neurogenic Orthostatic Hypotension (nOH) to be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) in San Diego from April 5-9, 2025.
The presentations, scheduled for April 7, 2025, will showcase findings from Studies 169 and 170, which led to the ongoing Phase 3 confirmatory CYPRESS Study 197 focusing on nOH in multiple system atrophy patients. Two key presentations will be delivered:
- NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in nOH Patients
- The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study
Theravance Biopharma (TBPH) reported strong Q4 and FY 2024 results, with YUPELRI achieving record US net sales of $66.7M in Q4 (up 10% YoY) and $238.6M for FY2024 (up 8% YoY). TRELEGY global net sales reached $3.46B in FY2024, up 26% YoY, triggering a $50M milestone payment to TBPH.
Q4 financial highlights include revenue of $18.8M from Viatris collaboration, R&D expenses of $9.5M, and SG&A expenses of $18.5M. The company ended Q4 with $88.4M in cash, excluding the $50M TRELEGY milestone received in February 2025.
For 2025 guidance, TBPH expects R&D expenses of $32-38M and SG&A expenses of $50-60M (excluding share-based compensation). The CYPRESS study for ampreloxetine remains on track to enroll its final patient by mid-2025.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation is scheduled for Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT).
The company will engage in in-person meetings with the investment community during the conference. Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) has announced it will release its fourth quarter and full year 2024 financial results and business update after market close on February 26, 2025. The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.
Interested participants can pre-register for the telephone conference call through the provided link. The webcast will be accessible through Theravance Biopharma's website under the Investors section, Events and Presentations. A replay of the webcast will remain available on the company's website for 30 days until March 28, 2025.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).
Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) has announced that its management team will be conducting investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, CA. Interested investors can request one-on-one meetings with the management team by contacting the company's investor relations department.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will engage in a Fireside Chat on Tuesday, December 3 at 11:15 am EST, alongside hosting in-person meetings with the investment community. The event will be accessible via webcast on Theravance.com under the Investors section, with a replay available for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2024 results, highlighting strong performance in key areas. YUPELRI net sales reached $62.2M, a 7% YoY increase and 14% QoQ growth. TRELEGY sales hit $789M, up 17% YoY. The company formed a Strategic Review Committee to explore alternatives for unlocking shareholder value. R&D expenses were $9.3M, while SG&A expenses stood at $16.9M. A non-cash impairment charge of $1.6M was recorded. Net loss was $12.7M, impacted by the impairment. Cash reserves totaled $91.4M. The company expects R&D expenses of $30-36M and SG&A expenses of $45-55M for full-year 2024. A settlement agreement with Qilu resolved ongoing patent litigation over YUPELRI.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its third quarter 2024 financial results announcement and business update for November 12, 2024, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EST on the same day. Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through Theravance's website. A replay will be available online for 30 days until December 12, 2024.